

Risk stratification of diabetic patients with unusual cardiac symptoms using a myocardial perfusion scan

Shirin Sarejloo⁽¹⁾, Fatemeh Dehghani⁽¹⁾, Mohammad Reza Hatamnejad⁽²⁾, Soodeh Jahangiri⁽²⁾, Tahereh Ghaedian⁽¹⁾, Maryam Salimi⁽³⁾, Hamed Bazrafshan Drissi⁽¹⁾

Original Article

Abstract

BACKGROUND: Autonomic nervous system dysfunction in diabetic patients can result in an atypical presentation of cardiovascular disease that can be missed. We aimed to use single-photon emission computed tomography (SPECT) to assess cardiovascular disease (CAD) in diabetic patients with atypical pain to determine whether the pain above reflects the CAD.

METHODS: Diabetic patients with atypical cardiac symptoms were referred to the SPECT department. Demographic data such as age, gender, diabetes status, and other underlying diseases were gathered. A myocardial perfusion scan was then performed. The results were recorded to evaluate the risk of myocardial ischemia and the degree of coronary artery involvement in a non-invasive manner.

RESULTS: The study included 222 (177 female) subjects with mean ages of 63.01 ± 11.62 and 59.41 ± 9.19 in positive and negative SPECT, respectively. The most common symptoms were atypical chest pain (51.8%), followed by shortness of breath (50.5%), nausea, and syncope (0.9%). Cardiac parameters, such as the summed stress score (SSS), summed rest score (SRS), total perfusion deficit in stress (TPD-s), total perfusion deficit in rest (TPD-r), were significantly higher in the group with coronary artery involvement ($P < 0.001$). However, ejection fraction (EF), end-diastolic volume (EDV), and end-systolic volumes (ESV) parameters were not ($P = 0.328, 0.351, \text{ and } 0.443$, respectively).

CONCLUSIONS: The mere presence of diabetes does not necessitate any additional diagnostic tests beyond those required for the general population, and it is possible to follow a diagnostic course similar to that of the general population.

Keywords: Diabetes Mellitus, Coronary Artery, Myocardial Perfusion Scan, Atypical Presentation, Atherosclerosis

Date of submission: 2021-Aug-12, Date of acceptance: 2022-Aug-29

Introduction

Although the risk of cardiovascular events in diabetic patients has decreased substantially in recent decades, it remains higher than in the general population. Furthermore, many people with diabetes do not survive their first cardiovascular event; if they do, their mortality is higher than those without diabetes^{1, 2}. The issues above have made cardiologists more sensitive to any atypical pain among people

with diabetes, causing them to perform excessive and even illogical evaluations of cardiac events.

How to cite this article: Sarejloo S, Dehghani F, Hatamnejad MR, Jahangiri S, Ghaedian T, Salimi M, Bazrafshan Drissi H. Risk stratification of diabetic patients with unusual cardiac symptoms using a myocardial perfusion scan. RYA Atheroscler 2023; 19: 44-52.

1- Al-Zahra Charity Hospital, Department of Cardiology Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

3- Shiraz University of Medical Sciences, Shiraz, Iran

Address for correspondence: Hamed Bazrafshan Drissi; Department of Cardiology Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Email: hamedbazrafshan@yahoo.com

On the other hand, the clinical implications of coronary disease in diabetic patients with altered pain perception remain debatable. Some researchers have found no differences in atypical or silent coronary cardiac disease (CAD) presentations in diabetic patients compared to non-diabetics³⁻⁵. In contrast, others reported that the presentation above is more frequent in diabetic patients with acute myocardial infarction^{6, 7}, implying that some associate type 2 diabetes with cardiovascular disease⁸. The patients above are admitted to the hospital and subjected to additional testing, imaging, and even invasive procedures such as coronary angiography. This approach leads to unnecessary hospitalization and cost.

There are several methods for assessing CAD. Angiography, considered an invasive method, detects various amounts of CAD regardless of whether myocardial perfusion was compromised. On the other hand, Single-photon emission computed tomography (SPECT) can distinguish those CADs causing a defect in myocardial perfusion⁹.

According to the preceding, we aimed to assess the risk of ischemia in those diabetic patients with atypical problems. We used SPECT, which is non-invasive and less expensive than diagnostic angiography.

Materials and Methods

All diabetic patients with unusual cardiac symptoms referred to the clinical centers between April 2018 to April 2019 were included in this cross-sectional study. A readily available sampling method was used for this study. Past medical history of diabetes, the presence of any of the unusual cardiac symptoms such as non-angina Pectoris (spotted, burning, or related to breathing), shortness of breath, nausea, vomiting, abdominal pain, weakness, lack of significant electrocardiogram (ECG) change, and standard cardiac-related biomarkers were all considered inclusion criteria. Diabetic patients with a positive history of myocardial infarction, valvular disorders, pulmonary artery hypertension, ejection fraction less than 55%, previous coronary angiography, percutaneous

coronary intervention (PCI), coronary artery bypass grafting (CABG) were excluded from the study.

All patients included in our study provided written informed consent. The purpose of this study was fully explained to the patients, and they were assured that the researcher would keep their information confidential. Similarly, IRBs of the authors' affiliated institutions have approved this research.

Demographic data, such as age and gender, were collected along with diabetes-related information such as duration of disease, type of diabetes, the status of follow-up, type of medication used for diabetes, and the presence of other underlying diseases. Hemoglobin A1c (HbA1c) levels were retrieved and recorded from recent tests to quantify the patient's blood sugar control. Heart SPECT was performed in these patients to assess the risk of myocardial ischemia and the extent of coronary artery involvement in a non-invasive manner. The results were recorded and re-interpreted by the scanning faculty. Patients who had CAD based on SPECT results were classified as positive, and those with no evidence of CAD (negative group) were compared regarding various parameters.

The cardiac-related parameters including summed stress score (SSS), summed rest score (SRS), total perfusion deficit in stress (TPD-s), total perfusion deficit in rest (TPD-r), ejection fraction (EF), end-diastolic volume (EDV), and end-systolic volumes (ESV) were assessed in all involved patients. Then the obtained values were compared between the two groups.

Statistical analysis

Descriptive statistics, including mean and dispersion indices, such as the amplitude of changes and standard deviation for quantitative variables and frequency percentage for qualitative variables, were used to describe the data. The data's normality was checked using the Shapiro-Wilk test and kurtosis and skewness indices. Data analysis was performed using Independent T-Test and Chi-Square Test or Fisher's Exact Test if the Chi-Square statistic was inappropriate. Likewise, the odds ratio

and 95% confidence interval were calculated using the logistic regression model. Statistical Package for the Social Sciences (SPSS) statistical software version 22 was used for data analysis (10). P-value <0.05 was considered statistically significant.

Results

A total of 222 subjects met the eligibility criteria, were enrolled, and followed up until the end of our study. Among these, 49 (22.1%) had some degree of coronary artery disease, and 173 (87.9%) were considered normal, and these two groups were used as a basis for

further comparisons in subsequent analyses. Table 1 demonstrates the demographic data between the two groups and the type and duration of diabetes in each group.

The age difference between the two groups with and without coronary artery involvement is statistically significant, with the subject having a higher mean age. Men were also significantly more likely to have coronary artery disease (CAD) than women (95% CI-1.17 92 4.92 and OR = 2.4). There was no significant difference between the two types, nor was there a difference in the duration of diabetes or the level of HbA1c in CAD (P. value: 0.127, 0.761, and 0.699, respectively).

Table 1. Demographic data of diabetic patients with positive and negative SPECT

Variable	Study Groups		P. value
	Positive SPECT ^c n= 49	Negative SPECT n= 173	
*Age: year± SD ^a	63.01± 11.62	59.41± 9.19	0.024
**Sex: number (%)			0.015
	Female	33 (67.3)	144 (83.2)
	Male	16 (32.6)	29 (16.8)
**Type of Diabetes: number (%)			0.127
	Type 1	7 (25)	21 (75)
	Type 2	42 (22)	149 (78)
*Duration of Diabetes (year):	8.38± 6.45	8.71± 6.75	0.761
*HbA1c ^b (mmol/mol)	6.69± 1.22	6.71± 1.42	0.699

^a SD: Standard deviation; ^b HbA1c: Glycated hemoglobin; ^c SPECT: Single-photon emission computed tomography; Binary factors are represented by number (percentage); continuous variables are illustrated as mean ± SD

* T-Test; ** Chi-square test

Table 2. The frequency and extent of coronary artery involvement based on cardiac scans in both groups

Coronary artery involvement	Frequency (%)
Normal	173 (77.9%)
Mild	44 (19.8%)
Moderate	3 (1.4%)
Severe	1 (0.5%)
Myocardial infarction	1 (0.5%)
Total	222 (100%)

Table 3 compares the types of drugs used in the two groups in any of the drugs tested. There was no statistically significant difference

between the two groups with or without coronary artery involvement.

In terms of underlying diseases and risk factors, the Chi-square test and odds ratio (OR) was used to compare the two groups with and without coronary artery involvement, proven by SPECT. According to the analysis summarized in Table 3, there was no significant relationship between these factors and CAS.

In terms of signs and symptoms, the most common are chest pain (51.8%), shortness of breath (50.5%), weakness or lethargy (23.4%), nausea (0.9%), and syncope (0.9%) being the rarest (Table 4).

Table 3. The effect of medical, family, and drug history on CAD among diabetic patients with atypical pain

variable	CAD ^a		OR ^b (95%CI) ^c	P-value
	Positive n= 49	Negative n= 173		
*Drug history				
<i>Citalopram</i>	0	2 (1.1%)	-	0.450
<i>Nitrates</i>	8 (16.8%)	22 (12.7%)	1.33 (0.55- 3.22)	0.514
<i>Aspirin</i>	11 (22.4%)	56 (32.4%)	0.60 (0.28- 1.27)	0.182
<i>Statins</i>	20 (40.8%)	85 (49.1%)	0.71 (0.37- 1.35)	0.303
<i>ACEI ^d/ARB ^e</i>	30 (61.2%)	90 (51.0%)	1.45 (0.76- 2.78)	0.254
<i>Insulin</i>	7 (14.3%)	16 (9.2%)	1.63 (0.63-4.23)	0.307
<i>Oral DM ^f Medication</i>	41 (85.4%)	144 (83.2%)	1.18 (0.48-2.88)	0.717
<i>Beta-blocker</i>	11 (22.4%)	41 (23.7%)	0.93 (0.43-1.98)	0.855
<i>Diuretics</i>	5 (10.2%)	13 (7.5%)	1.39 (0.47-4.13)	0.543
<i>Pantoprazole</i>	1 (2%)	3(1.7%)	1.18 (0.12-11.6)	0.887
<i>Levothyroxine</i>	0	10 (5.8)	-	0.122
<i>Clopidogrel</i>	0	2 (1.2)	-	0.450
<i>CCBs ^g</i>	10 (20.4%)	29 (16.8)	1.27 (0.27- 2.83)	0.554
*Past medical history				
<i>Asthma</i>	0 (0%)	1 (0.6%)	-	0.919
<i>Hypertension</i>	38 (77.6%)	113 (65.3%)	1.83 (0.87-3.84)	0.105
<i>Hyperlipidemia</i>	26 (53.1%)	93 (53.8%)	0.97 (51-1.83)	0.931
<i>Liver Disease</i>	2 (4.1%)	3 (1.7%)	2.41 (0.39-14.85)	0.328
<i>Renal Disease</i>	2 (4.1%)	6 (3.5%)	1.18 (0.23-6.06)	0.839
<i>Smoking</i>	8 (16.8%)	17 (9.8%)	1.71 (0.72-4.43)	0.204
<i>Hypothyroidism</i>	1 (2%)	6 (3.5%)	0.58 (0.06-4.9)	0.614
<i>Hyperthyroidism</i>	0	1 (0.6%)	-	-
<i>Obesity (body mass index>25)</i>	5 (10.2%)	23 (13.3%)	0.74 (0.26- 2.06)	0.565
<i>Rheumatoid arthritis</i>	1 (2%)	1 (0.6%)	3.5 (0.22-58.36)	0.339
<i>Cerebral vascular accident</i>	0	2 (1.2%)	-	0.45
positive Family History	1 (2%)	15 (8.7%)	0.25 (0.02-1.7)	0.113

^a CAD: Coronary Artery Disease; ^b OR: Odds Ratio; ^c CI: Confidence Interval; ^d ACEI: Angiotensin-Converting Enzyme Inhibitor; ^e ARB: Angiotensin Receptor Blocker; ^f DM: Diabetes Mellitus; ^g CCB: Calcium Channel Blocker
* Chi-square test; ** Fisher exact test

Except for abdominal pain, there was no statistically significant difference between the two groups in terms of these symptoms (8.2% vs. 1.2%). In other words, while these symptoms do not help diagnose the disease and cannot be used as a warning sign, abdominal can predict coronary artery involvement even though it could be more accurate.

The Chi-Square test results revealed no

statistically significant difference between the two groups, implying that the distribution of symptoms in both groups is the same (p.value=0.768) (Table 4).

Regarding the cardiac-related parameters, there was a statistically significant difference in SSS, SRS, TPD-s, and TPD-r. However, EF, EDV, and ESV did not show a statistically significant difference between the two groups (Table 4).

Table 4. Unusual signs and symptoms in positive and negative SPECT among diabetic patients

variable	CAD ^a		OR ^b (95%CI) ^c	P-value
	Positive n= 49	Negative n= 173		
	[*] Signs and symptoms: number (%)			
<i>Nausea: 2</i>	1 (2)	1 (0.6)	3.58 (0.22- 58.35)	0.339
<i>Syncope: 2</i>	2 (4.1)	0	0	0.450
<i>Vertigo: 9</i>	2 (4.1)	7(4.0)	1 (0.2- 5.02)	0.991
<i>Abdominal pain: 6</i>	4 (8.0)	2 (1.2)	7.6 (1.34- 42.2)	0.008
<i>Chronic fatigue: 13</i>	2 (4.1)	11 (6.4)	0.62 (0.13-2.92)	0.549
<i>Dyspnea: 112</i>	22 (44.9)	90 (62.9)	0.75 (0.39- 1.42)	0.379
<i>Sweating: 9</i>	1 (2.0)	8	0.43 (0.05- 3.52)	0.418
<i>Weakness and lethargy: 52</i>	14 (28.6)	38 (22.0)	1.42 (0.69- 2.91)	0.335
<i>Atypical chest pain: 115</i>	26 (53.1)	89 (51.4)	0.06 (0.56- 2.01)	0.842
<i>Palpitation: 30</i>	7 (14.3)	23 (13.3)	1.08 (0.43- 2.7)	0.858

^aCAD: Coronary Artery Disease; ^b OR: Odds Ratio; ^c CI: Confidence Interval;

^{*} Chi-square test or Fisher exact test

Table 5. SPECT-related results of positive and negative SPECT scans among diabetic patients

*Variable	Study Groups		P. value
	Positive SPECT ^a n= 49	Negative SPECT n= 173	
SSS ^b	7.68± 4.95	3.45± 2.87	<0.001
SRS ^c	2.54± 3.40	0.91±1.60	<0.001
TPD-s ^d	8.93± 5.71	3.99± 3.11	<0.001
TPD-r ^e	2.52±3.60	.0.87± 1.46	<0.001
EF ^f	72.97± 9.46	71.22± 9.46	0.328
EDV ^g	67.58± 25.14	72.02± 25.64	0.351
ESV ^h	20.35± 12.03	22.58± 16.61	0.443

^a SPECT: Single-photon emission computed tomography; ^b SSS: summed stress score; ^c SRS: summed rest score; ^d TPD-s: Total perfusion deficit in stress; ^e TPD-r: Total perfusion deficit in rest; ^f EF: Ejection fraction; ^g EDV: end-diastolic volume; ^h ESV: end-systolic volumes

^{*} T-Test

Discussion

Diabetics' altered perception of cardiac-related pain is primarily attributed to autonomic neuropathy disrupting sensory heart innervation, which then influences pain thresholds^{11,12}. A subsequent study discovered that the actual prevalence of CAD among atypical diabetic patients was lower than previously thought^{13,14}. Contradictory reports,

and the economic and psychological burden imposed on families and the health system for excessive workup of these patients, prompted us to evaluate the CAD in diabetic patients presenting with unusual symptoms. Diabetes, especially in young people, cannot be a sign of CAD in the presence of atypical cardiac symptoms, as will be discussed further.

In diabetic patients with favorable evidence for CAD, SSS, SRS, TPD-s, and

TPD-r were significantly higher than in negative counterparts. These findings support the utility of SPECT in detecting CAD. Previous studies in both symptomatic and asymptomatic patients have also demonstrated high SPECT accuracy¹⁵⁻¹⁷. As a result, we used it to assess the prevalence of CAD in diabetic patients exhibiting unusual symptoms.

Except for abdominal pain, there was no significant difference between atypical cardiac symptoms and CAD in diabetic patients based on our findings and statistical analysis. According to some reports, the current results favor nontypical diabetic patients^{18, 19}. On the contrary, several studies have found that shortness of breath or dyspnea is a significant predictor of CAD in diabetics²⁰⁻²⁵. Furthermore, some researchers linked dyspnea to coronary artery disease²⁶. According to the statements above, even in the absence of typical cardiac-related symptoms, dyspnea, and abdominal pain could be considered noticeable in diabetic patients for further CAD screening.

The current evidence indicates that people with diabetes with CAD were significantly older and male. However, the gender distribution in various studies is still being debated, and it appears that it cannot be an independent factor for CAD in diabetic patients^{27, 28}. Older diabetic patients are more likely to have coronary artery involvement and should undergo diagnostic tests like SPECT and angiography. Zellweger et al.²⁸ reported a cut-off in 2014, conducting a study among 313 DM patients with abnormal myocardial perfusion single-photon emission computed tomography (MPS) and 87 DM individuals with average MPS. Paillole et al. also suggested that patients be older than 60 for more accurate screening of atypical symptomatic patients²⁹. Although the sample size and the eligibility criteria were different in the studies above, all of them reported that unusual cardiac symptoms had represented CAD rarely.

In SPECT, there was no statistically significant relationship between the type of diabetes (type 1 or 2) and duration of

diabetes with coronary artery disease, despite previous research suggesting that prolonged diabetics (more than 20 years after type 1 diabetes or ten years after type 2 diabetes) had a higher risk of asymptomatic ischemia and CAD⁴. Kim et al. also discovered that having diabetes for a longer duration is associated with a greater extent, prevalence, and severity of CAD⁷. Furthermore, no drugs, including various insulins and oral anti-diabetic drugs, were found to be significantly associated with coronary artery disease. However, when calculating each group's OR, it is observed that aspirin, statins, and beta-blockers have reduced the chances of CAD. This relationship may become significant as the study population grows. Aspirin's efficacy was established in a powered RCT³⁰ approved by Rocca et al.³¹. Gupta et al.³²) precisely described other pharmacological managements in 2019, and the beneficial use of statins, beta-blockers, and aspirin was widely discussed and approved³³.

None of the underlying diseases, positive family history, obesity, or smoking were significantly associated with coronary artery disease in the comparison between the two groups with and without coronary artery involvement. However, in other studies, the prevalence of CAD in diabetic patients taking insulin or having high blood pressure at the same time has been significantly higher^{4, 29}. Some variations are due to the study population in each study. Some studies collect samples from people referred to tertiary care centers, while others collect samples from outpatient clinics. The severity of diabetes in the first group is higher than in the second group. Therefore, the results of the studies are also different. Overall, we believed that comorbidities and diabetes duration could not be considered independent risk factors for CAD.

This study had some limitations. Because the duration of diabetes was self-reported, it may have been underestimated or overestimated. Likewise, because it is a single-center study with a small sample size, it is still being determined whether the findings can be

generalized to other populations.

Conclusion

To summarize what has been said thus far, the mere presence of diabetes does not necessitate more diagnostic tests than the general population, and it is possible to go through a diagnostic process similar to the general population in treating diabetic patients with unusual cardiac symptoms. This study can be a foundation for more extensive cohort studies with larger study populations and long-term follow-up of patients following the onset of unusual cardiac symptoms to assess the annual incidence of cardiovascular events and death due to cardiac causes in these patients. Similarly, diagnostic, follow-up and treatment algorithms can be developed for patients of various ages.

Acknowledgment

CAD	Coronary Artery Disease
WHO	World Health Organization
AMI	Acute Myocardial Infarction
LV	Left Ventricle
PCI	Percutaneous Coronary Intervention
CABG	Coronary Artery Bypass Grafting
PET	Positron Emission Tomography
SPECT	Single Photon Emission Computed Tomography
OR	Odds Ratio
NPV	Negative Prognostic Value
DM	Diabetes Mellitus
IDDM	Insulin-Dependent Diabetes Mellitus
NIDDM	Non-Insulin Dependent Diabetes Mellitus
ROC Curve	Receiver Operating Characteristic Curve
HTN	Hypertension
HLP	Hyperlipidemia
RA	Rheumatoid Arthritis
ACEI	Angiotensin-Converting Enzyme Inhibitor
ARB	Angiotensin Receptor Blocker
CCB	Calcium Channel Blocker

References

1. Valensi P, Henry P, Boccara F, Cosson E, Prevost G, Emmerich J, et al. Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. *Diabetes Metab.* 2021; 47(2): 101185.
2. Moshfegh H, Tajeddini F, Pakravan HA, Mahzoon M, Yazdi EA, Drissi HB. A validated reduced-order dynamic model of nitric oxide regulation in coronary arteries. *Comput Biol Med.* 2021; 139: 104958.
3. Hatamnejad MR, Heydari AA, Salimi M, Jahangiri S, Bazrafshan M, Bazrafshan H. The utility of SYNTAX score predictability by electrocardiogram parameters in patients with unstable angina. *BMC Cardiovasc Disord.* 2022; 22(1): 1-11.
4. Sakboonyarat B, Rangsin R. Prevalence and associated factors of ischemic heart disease (IHD) among patients with diabetes mellitus: a nationwide, cross-sectional survey. *BMC Cardiovasc Disord.* 2018; 18(1): 151.
5. Nematollahi MA, Askarinejad A, Asadollahi A, Salimi M, Moghadami M, Sasannia S, et al. Association and Predictive Capability of Body Composition and Diabetes Mellitus Using Artificial Intelligence: A cohort study. 2022. <https://doi.org/10.21203/rs.3.rs-1675052/v1>
6. Jahangiri S, Mousavi SH, Hatamnejad MR, Salimi M, Bazrafshan H. Prevalence of non-steroidal anti-inflammatory drugs (NSAIDs) use in patients with hypertensive crisis. *Health Sci Rep.* 2022; 5(1): e483.
7. Kim J-J, Hwang B-H, Choi IJ, Choo E-H, Lim S, Kim J-K, et al. Impact of diabetes duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 diabetic patients: evaluation by coronary CT angiography. *Eur Heart J Cardiovasc Imaging.* 2015; 16(10): 1065-73.
8. Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder RE. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? *Diabetes care.* 2017; 40(7): 813-20.
9. Yamagishi M, Tamaki N, Akasaka T, Ikeda T, Ueshima K, Uemura S, et al. JCS 2018 guideline on diagnosis of chronic coronary heart diseases. *Circ J.*

- 2021; 85(4): 402-572.
10. Statistics I. IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Google Search. 2013.
 11. Omerbašić M, Glavić J, Mišković A, Bardak B, Cvitkušić Lukenda K, Miškić B. Silent Acute Myocardial Infarction In Diabetic Patients In Emergency Medicine. *Acta Med Croatica*. 2020; 74(Supl 1): 15-9.
 12. Balcioğlu AS, Müderrisoğlu H. Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment. *World J Diabetes*. 2015; 6(1): 80-91.
 13. Akın H, Bilge Ö. Relationship between frontal QRS-T duration and the severity of coronary artery disease in who were non-diabetic and had stable angina pectoris. *Anatol J Cardiol*. 2021; 25(8): 572-578.
 14. van Oosterhout RE, de Boer AR, Maas AH, Rutten FH, Bots ML, Peters SA. Sex Differences in Symptom Presentation in Acute Coronary Syndromes: A Systematic Review and Meta-analysis. *J Am Heart Assoc*. 2020; 9(9):e 014733.
 15. Chang C-W, Liao K-m, Chang Y-T, Wang S-H, Chen Y-c, Wang G-C. The first harmonic of radial pulse as an early predictor of silent coronary artery disease and adverse cardiac events in type 2 diabetic patients. *Cardiol Res Pract*. 2018; 2018.
 16. Dewey M, Siebes M, Kachelrieß M, Kofoed KF, Maurovich-Horvat P, Nikolaou K, et al. Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia. *Nat Rev Cardiol*. 2020; 17(7): 427-50.
 17. Schinkel AF, Elhendy A, Van Domburg RT, Bax JJ, Valkema R, Roelandt JR, et al. Long-term prognostic value of dobutamine stress 99mTc-sestamibi SPECT: single-center experience with 8-year follow-up. *Radiology*. 2002; 225(3): 701-6.
 18. Valensi P, Henry P, Boccara F, Cosson E, Prevost G, Emmerich J, et al. Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. *Diseases Metab*. 2021; 47(2): 101185.
 19. Thuresson M, Jarlöv MB, Lindahl B, Svensson L, Zedigh C, Herlitz J. Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes. *Am Heart J*. 2005; 150(2): 234-42.
 20. Abidov A, Rozanski A, Hachamovitch R, Hayes SW, Aboul-Enein F, Cohen I, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. *N Engl J Med*. 2005; 353(18): 1889-98.
 21. Bazrafshan H. Translation of Goldberger's clinical electrocardiography book (9th edition) to Persian. Moalefan Farhikhte Publication. (https://nashr.sums.ac.ir/view_book.php?book=764); 2017.
 22. Bergeron S, Ommen SR, Bailey KR, Oh JK, McCully RB, Pellikka PA. Exercise echocardiographic findings and outcome of patients referred for evaluation of dyspnea. *J Am Coll Cardiol*. 2004; 43(12): 2242-6.
 23. Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. *Circulation*. 2002; 105(1): 32-40.
 24. Maffei E, Seitun S, Martini C, Guaricci AI, Tarantini G, van Pelt N, et al. Prognostic value of CT coronary angiography in diabetic and non-diabetic subjects with suspected CAD: importance of presenting symptoms. *Insights Imaging*. 2011; 2(1): 25-38.
 25. Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2020; 33(1): 1-41. e8.
 26. Marwick TH. Dyspnea and risk in suspected coronary disease. *New England Journal of Medicine*. 2005; 353(18): 1963-5.
 27. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?. *Eur J Radiol*. 2020; 126: 108961.
 28. Zellweger MJ, Maraun M, Osterhues HH, Keller U, Müller-Brand J, Jeger R, et al. Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy. *JACC Cardiovasc Imaging*. 2014; 7(10): 1001-10.
 29. Paillole C, Ruiz J, Juliard J, Leblanc H, Gourgon

- R, Passa P. Detection of coronary artery disease in diabetic patients. *Diabetologia*. 1995; 38(6): 726-31.
30. Group ASC. Effects of aspirin for primary prevention in persons with diabetes mellitus. *N Eng J Med*. 2018; 379(16): 1529-39.
31. Rocca B, Patrono C. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. *Diabetes Res Clin pract*. 2020;160:108008.
32. Gupta M, Tummala R, Ghosh RK, Blumenthal C, Philip K, Bandyopadhyay D, et al. An update on pharmacotherapies in diabetic dyslipidemia. *Prog Cardiovasc Dis*. 2019; 62(4): 334-41.
33. Akrami M, Izadpanah P, Bazrafshan M, Hatamipour U, Nouraein N, Drissi HB, et al. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. *BMC Cardiovascular Disorders*. 2021; 7;21(1): 583.